Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 413-420

  Wei, Jing ^a   Han, Bing ^a   Mao, Xiao Yun ^a   Wei, Min Jie ^a   Yao, Fan ^a   Jin, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chinese women; ER ; Familial breast cancer; Methylation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 3; ESTROGEN RECEPTOR 4; ESTROGEN RECEPTOR 5; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SIZE; CELL NUCLEUS; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA GENE; FAMILIAL CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; BREAST TUMOR; ETHNOLOGY; FAMILY HEALTH; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MIDDLE AGED; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CHINA; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; FAMILY HEALTH; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 84860266077     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0234-x     Document Type: Article

References (37)

1. Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens. Indian J Pathol Microbiol. 2009;52:477-81.
2. Narod SA. Genes, the environment, and breast cancer. Lancet. 2010;375:2123-4.
3. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800-9.
4. Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, et al. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res. 2007;9:R38.
5. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-28.
7. Brinkman JA, El-Ashry D. ER. re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia. 2009;14:67-78.
8. Flanagan J, Kugler S, Waddell N, Johnstone C, Marsh A, Henderson S, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Breast Cancer Res. 2010;12 Suppl 1:O4.
9. Yoshida T, Eguchi H, Nakachi K, Tanimoto K, Higashi Y, Suemasu K, et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis. 2000;21:2193-201.
10. Wirtenberger M, Tchatchou S, Hemminki K, Schmutzhard J, Sutter C, Schmutzler RK, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis. 2006;27:2201-8.
11. Wirtenberger M, Schmutzhard J, Hemminki K, Meindl A, Sutter C, Schmutzler RK, et al. The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis. 2007;28:423-6.
12. Tavassoli FA. Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification. Nat Clin Pract Oncol. 2005;2:116-7.
13. Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, et al. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hyper-methylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat. 2009;117:253-9.
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6.
15. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 1998;58:2515-9.
16. Kok LF, Lee MY, Tyan YS, Wu TS, Cheng YW, Kung MF, et al. Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 2010;281:293-300.
17. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, et al. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med. 2009;7:25.
18. TM in breast carcinoma by image analysis. Pathol Int. 2001;51:33-6.
19. Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2/neu amplification in breast cancer: Stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-21.
20. Murff HJ, Byrne D, Haas JS, Puopolo AL, Brennan TA. Race and family history assessment for breast cancer. J Gen Intern Med. 2005;20:75-80.
21. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12:537-44.
22. Pirouzpanah S, Taleban FA, Atri M, Abadi AR, Mehdipour P. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer. Cancer Causes Control. 2010;21:2101-11.
23. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 2007;81:280-7.
24. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000;60:4346-8.
25. Hockings JK, Thorne PA, Kemp MQ, Morgan SS, Selmin O, Romagnolo DF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res. 2006;66:2224-32.
26. Burkadze G, Khardzeishvili O, Gudadze M, Tsikhiseli G, Turashvili G. Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast. Georgian Med News. 2010;184-185:51-60.
27. Flanagan J, Kugler S, Waddell N, Johnstone C, Marsh A, Henderson S, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet. 2010;86:420-33.
28. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007;99:1683-94.
29. Huang YS, Zhi YF, Wang SR. Hypermethylation of estrogen receptor-alpha gene in atheromatosis patients and its correlation with homocysteine. Pathophysiology. 2009;16:259-65.
30. Asada H, Yamagata Y, Taketani T, Matsuoka A, Tamura H, Hattori N, et al. Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. Mol Hum Reprod. 2008;14:539-45.
31. Roos MA, Bock GH, Vries J, Vegt B, Wesseling J. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res. 2007;140:109-14.
32. Rossner Jr P, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, et al. Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009;13:3847-57.
33. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007;67:7746-55.
34. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, et al. Transcriptional regulation of estrogen receptoralpha by p53 in human breast cancer cells. Cancer Res. 2009;69:3405-14.
35. Mao XY, Fan CF, Zheng HC, Wei J, Yao F, Jin F. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. J Exp Clin Cancer Res. 2010;29:112.
36. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008;47:600-7.
37. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat. 2003;21:301-6.